5 Matching Annotations
  1. Aug 2026
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC13430211/
  3. Apr 2026
  4. aacrjournals.org aacrjournals.org
    DS-3939a: A TA-MUC1-directed Antibody-Drug Conjugate with Broad Anti-Tumor Activity
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/mct/article/25/1/7/771286/DS-3939a-A-TA-MUC1-Directed-Antibody-Drug
  5. Oct 2025
  6. www.sciencedirect.com www.sciencedirect.com
    TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S1535610825004040
  7. Apr 2025
  8. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Trop-2 expression in non–small cell lung cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11999141/
  9. Aug 2024
  10. aacrjournals.org aacrjournals.org
    Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/clincancerres/article/30/15/3179/746582/Sacituzumab-Govitecan-Demonstrates-Efficacy-across